The principal objective is to evaluate a cure rate and number of adverse events of with confirmed multidrug-resistant tuberculosis patient treated with a 9months regimen.
Study participants will be followed up, under existing protocol derived from a study protocol developed by the "Union internationale contre les maladies respiratoires" and carried out already in 9 Africans countries. Participants will be hospitalised for at least four month, period which they will be given treatments, assessed for adverse events, monitored for TB-MR strains using culture techniques, at the monthly basis. If patients found with negative sputum culture at month four they will be dischrged from the hospital, and then treated four an additional five montns and then follow up, clinically and biologically for an additional six months before being declared as cured.
Study Type
OBSERVATIONAL
Enrollment
23
Second generation of anti tuberculosis Kanamycine, Moxifloxacine,Prothionamide, isoniazide,Clofazimine, Ethambutol,Pyrazinamide
Centre de Recherches Médicales de Lambaréné
Lambaréné, Please Select, Gabon
cure rate post treatment
Proportion of participants alive and presented with negative sputum culture for TB and with the absence of clinical, X-Ray and biological disorders related to TB
Time frame: Six months post treatment
TB-culture
First TB culture negative time
Time frame: 4 months after start of the treatment
Regimen tolorability
treatment, safety through clinical and biological assessment
Time frame: Throughout treatment period (9months)
Adverse events
solicited and unsolicited adverse events
Time frame: duration of participant in the study (15months)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.